Lexeo Therapeutics, Inc. Common Stock (LXEO) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 546K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -546K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 21.79M | 23.12M | 21.65M | 30.69M | 33.8M | 27.38M | 31.54M | 23.55M | 23.29M | 14.97M | 20.27M | 13.97M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 6.63M | 6.91M | 5.95M | 15.97M | 16.63M | 9.02M | 8.12M | 6.99M | 7.55M | 6.76M | 3.03M | 2.74M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 15.7M | 16.21M | 15.7M | 14.72M | 17.17M | 18.37M | 23.42M | 16.56M | 15.74M | 8.21M | 17.25M | 11.24M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -546K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -22.33M | -23.12M | -21.65M | -30.69M | -33.8M | -27.38M | -31.54M | -23.55M | -23.29M | -14.97M | -20.27M | -13.97M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 33.94% | 15.58% | 31.37% | -30.31% | -45.14% | -82.86% | -55.59% | -68.52% | -20.74% | 1.47% | - | - |
| EBITDA | -21.79M | -22.58M | -21.12M | -30.18M | -33.3M | -26.86M | -31.03M | -23.05M | -22.82M | -14.48M | -19.81M | -13.53M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 34.58% | 15.95% | 31.95% | -30.9% | -45.97% | -85.45% | -56.63% | -70.4% | -21.08% | 1.82% | - | - |
| D&A (Non-Cash Add-back) | 546K | 538K | 530K | 510K | 501K | 521K | 509K | 496K | 476K | 490K | 460K | 446K |
| EBIT | -22.33M | -20.89M | -20.2M | -26.04M | -32.62M | -25.89M | -29.45M | -21.2M | -21.64M | -14.14M | -20.06M | -13.39M |
| Net Interest Income | 2.14M | 2.19M | 1.37M | 1.21M | 1.15M | 1.46M | 2.06M | 2.31M | 1.61M | 1.05M | 436K | 537K |
| Interest Income | 2.15M | 2.21M | 1.46M | 1.27M | 1.19M | 1.49M | 2.09M | 2.35M | 1.65M | 1.1M | 488K | 590K |
| Interest Expense | 17K | 25K | 82K | 59K | 40K | 30K | 35K | 35K | 37K | 50K | 52K | 53K |
| Other Income/Expense | 2.14M | 2.2M | 1.36M | 4.58M | 1.15M | 1.46M | 2.05M | 2.31M | 1.61M | 787K | 165K | 534K |
| Pretax Income | -20.2M | -20.92M | -20.28M | -26.1M | -32.66M | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M | -20.11M | -13.44M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -20.2M | -20.92M | -20.28M | -26.1M | -32.66M | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M | -20.11M | -13.44M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 38.16% | 19.31% | 31.22% | -22.91% | -50.61% | -82.73% | -46.65% | -58.01% | -16.21% | 2.68% | - | - |
| Net Income (Continuing) | -20.2M | -20.92M | -20.28M | -26.1M | -32.66M | -25.92M | -29.49M | -21.24M | -21.68M | -14.19M | -20.11M | -13.44M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.25 | -0.27 | -0.33 | -0.60 | -0.99 | -0.78 | -0.89 | -0.64 | -0.77 | -0.52 | -0.80 | -0.53 |
| EPS Growth % | 74.75% | 65.38% | 62.92% | 6.25% | -28.57% | -50% | -11.25% | -20.75% | -4.05% | 10.34% | - | - |
| EPS (Basic) | -0.25 | -0.27 | -0.33 | -0.60 | -0.99 | -0.78 | -0.89 | -0.64 | -0.77 | -0.52 | -0.80 | -0.53 |
| Diluted Shares Outstanding | 81.18M | 76.36M | 60.98M | 43.57M | 33.11M | 33.08M | 33.06M | 33M | 27.98M | 27.31M | 25.17M | 25.17M |
| Basic Shares Outstanding | 81.18M | 76.36M | 60.98M | 43.57M | 33.11M | 33.08M | 33.06M | 33M | 27.98M | 27.31M | 25.17M | 25.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |